Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Hangzhou Just Biotherapeutics held the grand opening ceremony for its R&D Center and Manufacturing Facility.
read more
Sen-Jam Pharmaceutical has executed a second strategic partnership with KVK Tech. KVK Tech is a Specialty Pharmaceutical Manufacturing company that will now be providing formulation and Chemistry, Manufacturing & Controls (CMC) for Sen-Jam ...
read more
Norwich focuses on manufacturing potent, solid dose products, including fast dissolve and controlled release tablets, while also providing a range of analytical services in-house.
read more
Hammock Pharmaceuticals has announced the execution of a license agreement with MilanaPharm/TriLogic Pharma for the exclusive global rights to their women's health and urology hydrogel technology platform.
read more
Hamilton Health Care System and Baxter International announced Hamilton is the first health system in the U.S. to use Baxter’s new PrisMax system.
read more
Inspirata announced its free remote pathology initiative, available to healthcare institutions looking to provide flexibility to their staff during COVID-19.
read more
Halozyme Therapeutics and Ventana Medical Systems, a member of the Roche Group, announced a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's ...
read more
Wednesday, April 13, 2022
Halozyme Therapeutics, Inc. and Antares Pharma, Inc. have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was ...
read more
Monday, November 21, 2016
Halozyme Therapeutics announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target ...
read more
Halozyme Therapeutics has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume CFO duties on June 15 and will work with Ramsay through a transition ...
read more
Halozyme Therapeutics has announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics...
read more
Halo Pharmaceutical, a rapidly growing Contract Development and Manufacturing Organization (CDMO) is very pleased to announce the appointment of Roberto Darienzo to the newly created position of Chief Operating Officer.
read more
Tuesday, October 14, 2025
Halo Pharma appointed Laurent Malgouyres as Site Director for its facility in Mirabel, Quebec, Canada. In his new role, Malgouyres will oversee production, quality, and overall site performance.
read more
Tuesday, December 16, 2025
Halo Pharma is expanding its manufacturing capabilities at its Whippany, New Jersey facility with the addition of a Gerteis Macro-Pactor®, a versatile roller compactor that enhances the company’s ability to manage complex formulations, improve ...
read more
Halo Pharma announces the formation of its Pediatric Center of Excellence in support of the development and manufacture of dosage forms tailored for pediatric indications.
read more